The latest price target for Diffusion Pharmaceuticals (NASDAQ: DFFN) was reported by HC Wainwright & Co. on August 16, 2022. The analyst firm set a price target for $9.50 expecting DFFN to rise to within 12 months (a possible 38.28% upside). 1 analyst firms have reported ratings in the last year.

The latest analyst rating for Diffusion Pharmaceuticals (NASDAQ: DFFN) was provided by HC Wainwright & Co., and Diffusion Pharmaceuticals upgraded their buy rating.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Diffusion Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Diffusion Pharmaceuticals was filed on August 16, 2022 so you should expect the next rating to be made available sometime around August 16, 2023.

While ratings are subjective and will change, the latest Diffusion Pharmaceuticals (DFFN) rating was a upgraded with a price target of $0.00 to $9.50. The current price Diffusion Pharmaceuticals (DFFN) is trading at is $6.87, which is within the analyst's predicted range.